Targeted Drug Delivery Technologies:
Players, products & prospects to 2015
| Price: £595.00 Approx $1,155.49 (USD) €888.70 (EUR) |
|
|---|---|
| Overview: | |
| Whilst many approved and developmental drugs are well-tolerated, numerous drugs need advanced delivery technologies to improve pharmacokinetics, decrease toxicity, increase tolerability and ultimately enhance the therapeutic index. Peripheral toxicity related to the systemic administration of compounds can be dose limiting. However, the application of drug carrier platforms (dendrimers, liposomes, polymers, micelles) can significantly improve bio-distribution, whilst the addition of a targeted ligand (antibodies, peptides, proteins, vitamins) can enhance the selective uptake of drugs to target tissues or cells, thereby minimizing non-specific binding to non-target tissue. It is estimated that the advanced drug delivery market was worth around US$6.5 billion in 2006 with around 50% derived from targeted carrier systems and the remainder derived from implants and intrauterine devices. Advances in polymer technologies have enabled delivery specialists to design carriers for targeted delivery either through direct drug conjugates or through polymer formulations. However, one vehicle may not meet all delivery needs and progress in liposome formulations has also met with considerable success. The role of Mabs Some developers have chosen to harness the natural ability of monoclonal antibodies to target cells and where they may not make the grade as an immunotherapeutic, they may become useful carriers for drugs and the delivery of diagnostics and radiation. In addition, an array of antibody fragments and other gene targeting agents (aptamers, oligonucleotides) are also under investigation as targeting ligands for delivery. This report identifies 25 companies which have active research and clinical programmes evaluating targeted delivery carriers. By 2015 we anticipate 15 of these companies may have new or improved formulations of approved products on the market that will help to address the high unmet clinical need for “targeted” therapies. It is anticipated that nearly 30 new products will enter the market to generate an additional US$2 billion in advanced drug delivery sales. These products cover a number of key therapy areas including, cancer, cardiovascular and infectious disease. Combination products are the future Over time the line between each delivery system will become blurred as combination delivery systems evolve to meet the specific needs for each therapy class. As advances in nanotechnologies help to miniaturize delivery platforms, developments in targeting vehicles will grow to ensure the specific and selective intracellular and intranuclear delivery – providing the right drug at the right time to the right cell. |
|
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr Cheryl Lee Barton / Publication Date: 17th November 2007
Contents:
Contents
Executive Summary 1
Competitor Ratio Analysis Summary 4
Introduction 7
Overview of delivery technologies for systemic targeted delivery: past,present & future 8
Systemic targeted delivery: motivators & resistors 9
Motivators 9
Resistors 9
Systemic targeted DELIVERY TECHNOLOGIES 10
Types of systemic targeted delivery platform in development in the pharma industry 10
Targeting ligands 10
Figure 1: Antibody-directed enzyme prodrug targeted delivery 12
Figure 2: Peptide-induced release for targeted delivery 13
Figure 3: Nucleomic mediated targeted intranuclear delivery 14
Figure 4: Vitamin mediated targeted intracellular delivery - cobalamin 15
Non-biological targeting platforms 15
Figure 5: Photosensitive targeted delivery 16
Current therapeutic applications for systemic targeted delivery 18
Leading systemic targeted products in development 18
Table 1: Approved systemic and targeted drugs 18
Future commercial applications & opportunities 20
STRATEGIES OF DRUG DELIVERY COMPANIES 21
Leading targeted drug delivery companies 21
Table 2: Leading systemic targeted delivery specialists 21
Partnerships & acquisitions 22
Strategic alliances 22
Strategic acquisitions 23
Table 3: Recent market activity in targeted delivery companies 23
Intellectual Property 24
Table 4: Targeted drug delivery patents 25
THE TARGETED Delivery MARKET 26
Now 2007 26
Table 5: Approved targeted delivery product sales 26
Future 2015 26
Table 6: Global controlled release product sales 27
Table 7: Novel targeted delivery product sales 27
COMPETITOR ANALYSIS 28
Movers & Shakers: Cutting edge or losing their grip 28
Table 8: Movers & shakers in targeted drug delivery systems 29
COMPANY PROFILES 30
Access Pharmaceuticals (www.accesspharma.com 30
Figure 6: Schematic of targeted nanoparticle 30
Table 9: Targeted delivery of cancer subtypes via folate polymer, Vitamin B12 polymer and biotin polymers 31
Table 10: Access Pharmaceuticals’ product pipeline 32
Table 11: Access Pharmaceuticals’ targeted delivery sales forecasts 32
ALZA (www.alza.com) 34
Table 12: ALZA’s product pipeline 35
Table 13: ALZA’s targeted drug delivery sales 35
Avidimer Therapeutics (www.avidimer.com) 36
Table 14: Avidimer’s product pipeline 37
Table 15: Avidimer's targeted drug delivery sales 37
Calando Pharmaceuticals (www. calandopharma.com) 38
Figure 7: Schematic of cyclodextrin polymeric nanoparticles 38
Table 16: Calando’s product pipeline 39
Table 17: Calando’s targeted delivery sales forecasts 39
Cell Therapeutics (www.ctiseattle.com) 40
Figure 8: CTI’s polyglutamate polymer technology 40
Table 18: CTI’s product pipeline 41
Copernicus Therapeutics (www.cgsys.com) 43
Table 20: Copernicus’ product pipeline 44
Table 21: Copernicus’ targeted delivery sales forecasts 44
Diatos SA (www.diatos.com) 45
Table 22: Diatos’ product pipeline 46
Table 23: Diatos’ targeted drug delivery sales 47
Enzon Pharmaceuticals, Inc. (www.enzon.com) 48
Table 24: Enzon’s product pipeline 49
Table 25: Enzon’s targeted product sales 50
Endocyte Inc. (www.endocyte.com) 51
Table 26: Endocyte’s product pipeline 52
Table 27: Endocyte’s targeted drug delivery sales 52
Eurand (www.eurand.com) 53
Table 28: Eurand’s product pipeline 54
ImmunoGen (www.immunogen.com) 55
Table 29: ImmunoGen’s product pipeline 56
Table 30: ImmunoGen’s targeted delivery sales 56
ImaRx Therapeutics (www.imarx.com) 57
Table 31: ImaRx’ product pipeline 57
Table 32: ImaRx’ targeted product sales 58
Insert Therapeutics (www.insertt.com) 59
Figure 9: Schematic of Cyclosert’s nanoparticle mediated drug delivery to solid tumours 59
Table 33: Insert Therapeutics’ product pipeline 60
Table 34: Insert Therapeutics' targeted product sales 60
Mirus Bio Corporation (www.mirusbio.com) 62
Figure 10: PolyConjugates – siRNA delivery system 62
Table 35: Mirus’ product pipeline 63
NanoBioMagnetics, Inc (www.nanobmi.com) 64
Table 36: NanoBioMagnetics’ product pipeline 64
Nanobiotix (www.nanobiotix.com) 66
Table 37: Nanobiotix’ product pipeline 66
NanoCarrier (www.nanocarrier.co.jp) 68
Figure 11: NanoCoat technology 68
Table 38: NanoCarrier’s product pipeline 69
Table 39: NanoCarrier’s targeted drug delivery sales 69
NeoPharm (www.neopharm.com) 70
Table 40: NeoPharm’s product pipeline 71
Table 41: NeoPharm’s drug delivery sales 71
Novosom AG (www.novosom.com) 73
Figure 12: Schematic of SMARTICLES mechanism of targeted delivery 73
Table 42: Novosom’s product pipeline 74
PCI Biotech AS (www.photocure.com) 75
Figure 13: Schematic of principle of PCI technology 75
Table 43: PCI’s product pipeline 76
Point BioMedical Corporation (www.pointbio.com) 77
Figure 14: Schematic of Point’s biSphere 77
Table 44: Point’s product pipeline 78
Quest PharmaTech (www.questpharmatech.com) 79
Table 45: Quest PharmaTech’s product pipeline 80
Seattle Genetics (www.seattlegenetics.com 81
Figure 15: Schematic of ADC’s 81
Table 46: Seattle Genetic’s product pipeline 82
Table 47: Seattle Genetic’s delivery sales 82
Starpharma (www.starpharma.com) 83
Table 48: Starpharma’s product pipeline 84
Supratek Pharma Inc. (www.supratek.com) 85
Table 49: Supratek’s product pipeline 86
Tekmira Pharmaceuticals Corporation (www.tekmirapharm.com) 87
Table 50: Tekmira’s product pipeline 88
Table 51: Tekmira’s targeted delivery sales forecasts 89
APPENDIX 1 90
Table 52: Global targeted approved drugs sales 2006A-20015E 90
APPENDIX 2 91
Table 53: Global targeted developmental drugs sales 2006A-20015E91
APPENDIX 3 93
Competitor Ratio Analysis Criteria 93
Table 54: Key targeted delivery companies by 2015 94
BIBLIOGRAPHY 95
GLOSSARY 96
ACRONYMS 102